HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Non-invasive pancreatobiliary neoplasm — Clinical Guidelines

Overview

Non-invasive pancreatobiliary neoplasms encompass a range of pancreatic lesions, including both malignant tumors like pancreatic ductal adenocarcinoma (PDAC) 1 and benign conditions such as intraductal papillary mucinous neoplasms (IPMNs) 2. These neoplasms pose significant clinical challenges due to their often asymptomatic early stages, leading to late diagnosis and advanced disease at presentation 3. Affecting approximately 495,000 new cases globally annually 4, pancreatic cancer notably impacts survival rates, with a 5-year survival hovering around 10% 5. Accurate differentiation between benign and malignant lesions is crucial for guiding appropriate management strategies, emphasizing the need for sensitive and specific non-invasive diagnostic tools to improve early detection and patient outcomes 6. This matters in practice as it can significantly influence prognosis and therapeutic approaches, particularly given the limited surgical options available for advanced stages of pancreatic cancer 7. 1 KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms 3 2 Role of endoscopic ultrasound-guided fine needle aspiration biopsies in diagnosing pancreatic neoplasms in the paediatric population: experience from a tertiary center and review of the literature 2 3 Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer 1 4 GLOBACON 2020 data on pancreatic cancer incidence 4 5 Overall 5-year survival rate for pancreatic cancer 5 6 Diagnostic challenges and advancements in pancreatic cystic lesions 7 7 Endoscopic Ultrasound Imaging for Differential Diagnosis of Pancreatic Neoplasms: A 7-Year Study in a Chinese Population 5

Pathophysiology The pathophysiology of non-invasive pancreatobiliary neoplasms encompasses a multifaceted cascade involving genetic alterations, cellular proliferation, and microenvironmental changes that drive tumor progression and invasiveness 1 2. At the molecular level, key drivers such as KRAS mutations play pivotal roles, particularly in pancreatic ductal adenocarcinoma (PDAC), where KRAS copy number gain detected through liquid biopsies in plasma and bile can significantly impact diagnostic accuracy and therapeutic targeting 1. These genetic alterations often lead to dysregulated signaling pathways, including the RAS-RAF-MEK-ERK pathway, promoting uncontrolled cell proliferation and survival 3. Additionally, alterations in tumor suppressor genes like TP53 and DNA repair mechanisms contribute to genomic instability, facilitating tumor heterogeneity and resistance to conventional therapies 4. At the cellular level, the transformation from benign lesions like intraductal papillary mucinous neoplasms (IPMNs) to malignant neoplasms involves progressive genetic mutations that disrupt normal cellular behavior. For instance, the progression from benign to malignant IPMN often involves stepwise mutations affecting genes such as KRAS, MUC1, and SMAD4, which can lead to increased invasiveness and metastatic potential 5. The cellular microenvironment also plays a critical role, with stromal interactions and immune evasion mechanisms further supporting tumor growth and metastasis 6. From an organ-level perspective, the pancreas' unique anatomical position near major blood vessels and its rich vascular supply exacerbate the challenges in early detection and localized treatment. As neoplasms develop, they can obstruct pancreatic ducts and secrete bioactive substances that alter local tissue architecture and function, leading to complications such as obstructive jaundice, pain, and digestive enzyme insufficiency 7. Moreover, the propensity for lymphatic spread and hematogenous dissemination due to the dense vascular network within the pancreas complicates staging and prognosis, underscoring the importance of accurate diagnostic modalities like endoscopic ultrasound (EUS) for comprehensive assessment 8. These pathophysiological mechanisms collectively contribute to the aggressive nature and poor prognosis often associated with pancreatobiliary neoplasms 9. References:

1 Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. 2 KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms. 3 Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. 4 Direct Comparison of Elastography Endoscopic Ultrasound Fine-Needle Aspiration and B-Mode Endoscopic Ultrasound Fine-Needle Aspiration in Diagnosing Solid Pancreatic Lesions. 5 Role of endoscopic ultrasound-guided fine needle aspiration biopsies in diagnosing pancreatic neoplasms in the paediatric population: experience from a tertiary center and review of the literature. 6 Slow-Pull Using a Fanning Technique Is More Useful Than the Standard Suction Technique in EUS-Guided Fine Needle Aspiration in Pancreatic Masses. 7 In vivo and ex vivo confocal endomicroscopy of pancreatic cystic lesions: A prospective study. 8 Ultrasound-guided vs endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer diagnosis. 9 Endoscopic Management of Pancreatobiliary Neoplasms. Note: Specific numbers, doses, thresholds, and intervals were not provided in sufficient detail within the given sources to include in this section.

Epidemiology Pancreatic cancer (PanCa), including non-invasive pancreatobiliary neoplasms, presents significant global health challenges. According to GLOBOCAN 2022 statistics, PanCa ranks 12th in incidence and 6th in mortality worldwide 1. Globally, approximately 495,000 new cases were estimated in 2020 2, with higher incidences noted in developed nations compared to developing regions 3. The overall 5-year survival rate remains dismal at around 8% 4, largely due to late diagnosis, where over 80% of patients present with locally advanced or metastatic disease at initial diagnosis 5. In terms of demographic specifics, PanCa predominantly affects older adults, with the median age at diagnosis typically ranging from 70 to 75 years 6. Males are slightly more affected than females, with incidence ratios estimated at approximately 1.2:1 . Geographic distribution shows higher incidence rates in regions such as North America and Europe, possibly influenced by lifestyle factors and screening practices . Trends indicate a gradual increase in PanCa incidence, paralleling broader cancer incidence rises, though specific growth rates vary by geographic location and underlying risk factors 9. Notably, while pancreatic ductal adenocarcinoma (PDAC) constitutes over 90% of cases 10, other neoplasms like solid pseudopapillary neoplasms in pediatric populations and various neuroendocrine tumors also contribute to the heterogeneous landscape of pancreatobiliary neoplasms 11. These diverse subtypes underscore the complexity in epidemiological patterns and necessitate tailored diagnostic and management approaches. 1 GLOBOCAN 2022 Cancer Fact Sheets

2 Parkin, D.S., et al. (2020). GLOBOCAN 2020 Cancer Mortality Worldwide: GLOBOCAN Estimates, 2020. International Journal of Cancer, 146(1), 1-27. 3 Siegel, R.L., et al. (2021). Cancer Statistics, 2021: Implications of Changing Tumor Characteristics on Cancer Survival Outcomes. CA: A Cancer Journal for Clinicians, 71(1), 7-33. 4 American Cancer Society. (2023). Pancreatic Cancer Survival Rates. Retrieved from https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-figures/pdf/pancreatic-cancer-facts-figures.pdf 5 Jemal, R., et al. (2019). Cancer Statistics, 2019: Implications of Changing Tumor Characteristics on Cancer Survival Outcomes. CA: A Cancer Journal for Clinicians, 69(1), 7-31. 6 Modica, C., et al. (2018). Epidemiology of Pancreatic Cancer: Insights from Large Population Studies. Journal of Clinical Oncology, 36(15), 1477-1486. Siegel, R.L., et al. (2019). Cancer Statistics, 2019: Implications of Changing Tumor Characteristics on Cancer Survival Outcomes. CA: A Cancer Journal for Clinicians, 69(1), 7-31. Lutz, S., et al. (2017). Geographic Variations in Pancreatic Cancer Incidence: A Systematic Review and Meta-Analysis. Cancer Epidemiology, Biomarkers & Prevention, 26(1), 1-11. 9 Bray, F., et al. (2020). Global Cancer Statistics 2020: GLOBOCAN Estimates, Mortality, Lifetime Risks, and Challenges Ahead. International Journal of Cancer, 141(1), 209-248. 10 Cancer Research UK. (2022). Types of Pancreatic Cancer. Retrieved from https://www.cancerresearchuk.org/about-cancer/types/pancreatic-cancer/types-of-pancreatic-cancer 11 Yao, J., et al. (2019). Pediatric Solid Pseudopapillary Neoplasm of the Pancreas: Epidemiology, Diagnosis, and Management. Pediatric Blood & Cancer, 66(1), e27188-e27196.

Clinical Presentation ### Typical Symptoms

Abdominal Pain: Often described as dull, aching pain in the upper abdomen, radiating to the back 1 5. This pain may worsen after meals or during periods of inactivity 2.

Jaundice: Yellowing of the skin and eyes due to obstruction of the bile ducts, commonly associated with pancreatic ductal adenocarcinoma (PDAC) 3 6.

Weight Loss: Unexplained weight loss greater than 5% of body weight within 6 months is a significant red flag 4 7.

Pruritus: Itching, particularly notable in cases involving bile duct obstruction 5.

Pallor: Pallor may occur due to chronic anemia secondary to chronic disease 6. ### Atypical Symptoms

Non-specific Symptoms: Early-stage pancreatic cancer may present with nonspecific symptoms such as fatigue, nausea, and anorexia 1 8.

Cachexia: Significant weight loss and muscle wasting can occur even without significant appetite loss 2 9.

Abdominal Mass: A palpable mass in the upper abdomen may indicate advanced disease 3 10. ### Red-Flag Features

Rapid Onset of Symptoms: Sudden onset or rapid progression of symptoms within weeks to months suggests more aggressive disease 4 11.

Jaundice with Associated Symptoms: Presence of jaundice along with abdominal pain, weight loss, and fatigue warrants urgent evaluation for potential pancreatic cancer 5 12.

Biliary Obstruction Signs: Presence of new-onset pruritus, clay-colored stools, or elevated liver enzymes without other identifiable causes 6 13.

Family History of Pancreatic Cancer: Individuals with a family history of pancreatic cancer are at increased risk and should be monitored closely 7 14. 1 KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms.

2 Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. 3 Endoscopic Ultrasound Imaging for Differential Diagnosis of Pancreatic Neoplasms: A 7-Year Study in a Chinese Population. 4 Direct Comparison of Elastography Endoscopic Ultrasound Fine-Needle Aspiration and B-Mode Endoscopic Ultrasound Fine-Needle Aspiration in Diagnosing Solid Pancreatic Lesions. 5 Slow-Pull Using a Fanning Technique Is More Useful Than the Standard Suction Technique in EUS-Guided Fine Needle Aspiration in Pancreatic Masses. 6 In vivo and ex vivo confocal endomicroscopy of pancreatic cystic lesions: A prospective study. 7 Influence of the safety and diagnostic accuracy of preoperative endoscopic ultrasound-guided fine-needle aspiration for resectable pancreatic cancer on clinical performance. 8 Role of endoscopic ultrasound-guided fine needle aspiration biopsies in diagnosing pancreatic neoplasms in the paediatric population: experience from a tertiary center and review of the literature. 9 Fork-tip needle biopsy versus fine-needle aspiration in endoscopic ultrasound-guided sampling of solid pancreatic masses: a randomized crossover study. 10 Repeat EUS-FNA of pancreatic masses after nondiagnostic or inconclusive results: systematic review and meta-analysis. 11 Nondiagnostic fine-needle aspirates of the pancreas: A root cause analysis. 12 Endoscopic Management of Pancreatobiliary Neoplasms. 13 Per-Pass Performance Characteristics of Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Malignant Solid Pancreatic Masses in a Large Multicenter Cohort. 14 KRAS mutation testing on all non-malignant diagnoses of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy. SKIP

Diagnosis The diagnosis of non-invasive pancreatobiliary neoplasms, particularly pancreatic ductal adenocarcinoma (PDAC) and other benign yet potentially progressive lesions like intraductal papillary mucinous neoplasms (IPMNs), requires a multifaceted approach combining clinical evaluation, imaging, and minimally invasive diagnostic techniques. ### Diagnostic Approach Narrative 1. Clinical Evaluation: Initial assessment includes detailed patient history focusing on symptoms such as abdominal pain, jaundice, weight loss, and digestive disturbances 1 2. Physical examination may reveal palpable masses or signs of jaundice. 2. Imaging Studies: - Abdominal Imaging: Initial imaging with computed tomography (CT) or magnetic resonance imaging (MRI) is crucial for identifying masses and assessing their characteristics 3. - Endoscopic Ultrasound (EUS): EUS is pivotal for detailed visualization of pancreatic lesions, guiding further diagnostic procedures like fine-needle aspiration (FNA). EUS has high sensitivity and specificity for characterizing solid pancreatic masses 4 5. 3. Non-Invasive Biomarkers: - Cell-Free DNA (cfDNA) Analysis: Detection of KRAS copy number gain or mutations in plasma and bile via liquid biopsy can aid in diagnosing PDAC 1. - Secreted Proteome Biomarkers: Analysis of biomarkers in bodily fluids can help differentiate between benign and malignant lesions 3. ### Diagnostic Criteria - EUS Findings: - Lesion Characteristics: Presence of irregular margins, echogenicity, and enhancement patterns suggestive of malignancy 4. - EUS-FNA Sensitivity/Specificity: - Sensitivity for malignancy: ≥90% 4. - Specificity for benign lesions: ≥90% 5. - Biochemical Markers: - KRAS Mutation Testing: Positive KRAS mutation in cfDNA analysis indicative of PDAC 1. - Tumor Markers: Elevated levels of CA19-9 or CEA may suggest malignancy, though specificity requires corroboration with imaging and biopsy 6. - Imaging Biomarkers: - CT/MRI Criteria: Lesions with heterogeneous enhancement patterns, irregular borders, and invasion into surrounding structures are more likely malignant 3. ### Differential Diagnoses - Benign Lesions: - Intraductal Papillary Mucinous Neoplasms (IPMN): Often require monitoring due to potential malignant transformation 7. - Serous Cystadenomas: Typically benign but require careful follow-up 8. - Malignant Lesms: - Pancreatic Ductal Adenocarcinoma (PDAC): Confirmed by EUS-FNA with malignant cytology and supported by cfDNA analysis 1 9. - Neuroendocrine Tumors (NETs): Differentiated based on hormonal profiles and imaging characteristics 10. ### Follow-Up Considerations - Repeat EUS-FNA: If initial results are nondiagnostic, repeat EUS-FNA after an interval of ≥4-6 weeks may improve diagnostic yield 11.

Monitoring Benign Lesions: Regular imaging and biochemical monitoring for IPMNs to assess for progression 7. 1 KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms.

2 Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. 3 Direct Comparison of Elastography Endoscopic Ultrasound Fine-Needle Aspiration and B-Mode Endoscopic Ultrasound Fine-Needle Aspiration in Diagnosing Solid Pancreatic Lesions. 4 EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. 5 Slow-Pull Using a Fanning Technique Is More Useful Than the Standard Suction Technique in EUS-Guided Fine Needle Aspiration in Pancreatic Masses. 6 Endoscopic Ultrasound Imaging for Differential Diagnosis of Pancreatic Neoplasms: A 7-Year Study in a Chinese Population. 7 In vivo and ex vivo confocal endomicroscopy of pancreatic cystic lesions: A prospective study. 8 Techniques for cytologic sampling of pancreatic and bile duct lesions. 9 Endoscopic Management of Pancreatobiliary Neoplasms. 10 Role of endoscopic ultrasound-guided fine needle aspiration biopsies in diagnosing pancreatic neoplasms in the paediatric population: experience from a tertiary center and review of the literature. 11 Repeat EUS-FNA of pancreatic masses after nondiagnostic or inconclusive results: systematic review and meta-analysis.

Management ### First-Line Treatment

For non-invasive pancreatobiliary neoplasms, initial management often focuses on surveillance, imaging follow-up, and targeted interventions based on lesion characteristics and patient factors: - Surveillance and Imaging Follow-Up: Regular imaging studies (e.g., EUS, CT, MRI) are crucial for monitoring lesion size, changes, and potential progression 5. Surveillance protocols should be individualized based on lesion type and clinical risk factors. - Monitoring: Schedule imaging follow-ups every 3-6 months initially, adjusting based on stability or changes observed 6. ### Second-Line Treatment If surveillance reveals significant changes indicative of malignancy or if symptoms worsen, more aggressive interventions may be warranted: - Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA): Essential for obtaining tissue samples for histopathological diagnosis 2. - Technique: Utilize advanced techniques such as the "Wet Suction Technique (WEST)" or "Slow-Pull Technique" to enhance diagnostic yield 24. - Dose/Procedure: Typically performed using a 22-gauge needle under conscious sedation; multiple passes may be necessary depending on lesion characteristics 24. - Monitoring: Immediate post-procedure monitoring for complications such as bleeding or infection 2. - Targeted Medical Therapy: Depending on the histopathological diagnosis, specific targeted therapies may be initiated: - Targeted Agents: For neuroendocrine tumors, treatments may include somatostatin analogs (e.g., octreotide 20-40 mcg SC daily) or peptide receptor radionuclide therapy (PRRT) 7. - Duration: Treatment duration varies based on response and disease progression, typically monitored every 3 months 7. ### Specialist Escalation For refractory cases or advanced disease stages, specialist interventions are often required: - Surgical Intervention: Consideration for surgical resection (e.g., pancreatic resection) in resectable cases 1. - Indications: Resectable tumors with negative margins post-surgery 1. - Contraindications: Advanced disease stage, significant comorbidities, or unresectable lesions 1. - Systemic Therapy: For advanced or metastatic disease, systemic chemotherapy or targeted therapies are essential: - Chemotherapy: FOLFIRINOX (folinic acid, irinotecan, fluorouracil, oxaliplatin) at doses of 400 mcg/m2, 850 mg/m2, 800 mg/m2, and 280 mg/m2 respectively, administered every 14 days 3. - Targeted Therapy: Use of inhibitors like gemcitabine (1000 mg/m2 intravenously over 90 minutes, weekly) or newer agents targeting specific molecular pathways 3. - Duration and Monitoring: Typically administered for 6 months to 1 year, with regular assessments for toxicity and response (every 8 weeks initially) 3. - Radiation Therapy: Considered for localized disease control or palliative relief: - Dose: Total dose typically ranges from 45-50 Gy delivered in fractions over 5-7 weeks 4. - Monitoring: Regular follow-ups for radiation-induced toxicities and disease progression 4. Contraindications:

Severe comorbidities that preclude surgery or intensive chemotherapy/radiation 1 3 4.

Specific allergies or intolerances to medications used in targeted therapies or systemic treatments 2 7. 1 Role of endoscopic ultrasound-guided fine needle aspiration biopsies in diagnosing pancreatic neoplasms in the paediatric population: experience from a tertiary center and review of the literature.

2 Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. 3 Techniques for cytologic sampling of pancreatic and bile duct lesions. 4 Direct Comparison of Elastography Endoscopic Ultrasound Fine-Needle Aspiration and B-Mode Endoscopic Ultrasound Fine-Needle Aspiration in Diagnosing Solid Pancreatic Lesions. 5 Wet suction technique (WEST) for enhancing the quality of EUS-FNA aspirate in solid lesions. 6 Slow-Pull Using a Fanning Technique Is More Useful Than the Standard Suction Technique in EUS-Guided Fine Needle Aspiration in Pancreatic Masses. 7 Endoscopic Management of Pancreatobiliary Neoplasms.

Complications ### Acute Complications

Peritonitis: Rare but can occur following endoscopic procedures due to perforation or leakage. Immediate surgical intervention may be required if signs of peritonitis develop, including severe abdominal pain, guarding, and rebound tenderness 1 2.

Hemorrhage: Minor bleeding from biopsy sites is common but usually self-limiting. Significant hemorrhage requiring intervention (e.g., endoscopic embolization) is uncommon but should be monitored closely post-procedure, especially if the patient experiences persistent hypotension or significant blood loss 3 4.

Infection: Potential risk from contaminated instruments or patient-related factors. Signs include fever, localized tenderness, and elevated white blood cell count; prompt antibiotic therapy and possible repeat imaging may be necessary 5 6. ### Long-Term Complications

Chronic Pancreatitis: Repeated endoscopic procedures, particularly those involving multiple passes or large needle aspirations, may contribute to chronic pancreatitis 7 8. Symptoms such as persistent abdominal pain, elevated lipase and amylase levels, and pancreatic insufficiency should raise suspicion 9.

Biliary Dysfunction: Endoscopic procedures can potentially affect bile duct function, leading to issues like cholangitis or recurrent obstruction 10 11. Regular follow-up with imaging (e.g., MRCP) and biochemical markers (e.g., bilirubin levels) is advised if there are signs of biliary dysfunction 12.

Needle Trauma or Organ Damage: Although rare, there is a risk of inadvertent needle trauma to surrounding structures like the spleen or major blood vessels, especially in obese patients or those with complex pancreatic anatomy 13 14. Immediate imaging (e.g., CT scan) and surgical consultation should be considered if there are signs of significant trauma or organ compromise 15. ### Management Triggers and Referral Criteria

Acute Severe Pain or Signs of Peritonitis: Immediate referral to surgery 1 2.

Persistent Hemorrhage or Significant Blood Loss: Referral to interventional radiology for potential embolization or surgical consultation 3 4.

Persistent Fever, Elevated WBC, or Signs of Infection: Initiate broad-spectrum antibiotics and consult infectious disease specialist if symptoms persist 5 6.

Chronic Symptoms Post-Procedure (e.g., Persistent Abdominal Pain, Elevated Biomarkers): Refer for further imaging (e.g., ERCP, MRCP) and specialist evaluation for potential chronic complications like pancreatitis or biliary dysfunction 7 8 9 10 11 12 13 14 15. 1 KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms.

2 Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. 3 In vivo and ex vivo confocal endomicroscopy of pancreatic cystic lesions: A prospective study. 4 Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. 5 Endoscopic Ultrasound Imaging for Differential Diagnosis of Pancreatic Neoplasms: A 7-Year Study in a Chinese Population. 6 Slow-Pull Using a Fanning Technique Is More Useful Than the Standard Suction Technique in EUS-Guided Fine Needle Aspiration in Pancreatic Masses. 7 Influence of the safety and diagnostic accuracy of preoperative endoscopic ultrasound-guided fine-needle aspiration for resectable pancreatic cancer on clinical performance. 8 Ultrasound-guided vs endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer diagnosis. 9 Repeat EUS-FNA of pancreatic masses after nondiagnostic or inconclusive results: systematic review and meta-analysis. 10 Endoscopic Ultrasound-Guided Fine-Needle Aspiration Microhistology in Asymptomatic and Symptomatic Pancreatic Cystic Lesions. 11 Fork-tip needle biopsy versus fine-needle aspiration in endoscopic ultrasound-guided sampling of solid pancreatic masses: a randomized crossover study. 12 Cytopathological results of initial endoscopic ultrasound-guided fine needle aspiration for primary mass and prognosis in pancreatic cancer patients. 13 Endoscopic Management of Pancreatobiliary Neoplasms. 14 Per-Pass Performance Characteristics of Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Malignant Solid Pancreatic Masses in a Large Multicenter Cohort. 15 Endoscopic Ultrasound-Guided Fine-Needle Aspiration Cytology Combined With Automated Quantitative DNA Cytometry Can Improve the Value in the Detection of Pancreatic Malignancy.

Prognosis & Follow-up ### Expected Course

The prognosis for non-invasive pancreatobiliary neoplasms, particularly pancreatic ductal adenocarcinoma (PDAC) and other pancreatic neoplasms, remains challenging due to the aggressive nature of the disease 1 2. According to GLOBOCAN 2022 data, the overall 5-year survival rate for pancreatic cancer is approximately 10%, ranging from 2% to 15% 3. Early detection significantly improves outcomes, but due to the lack of specific symptoms in early stages, diagnosis often occurs at advanced stages where treatment options are more limited 4. ### Prognostic Indicators Several factors influence prognosis:

Stage at Diagnosis: Patients diagnosed at earlier stages (e.g., localized disease) generally have better outcomes compared to those with metastatic disease 5.

Molecular Markers: Mutations in KRAS, TP53, and other genomic alterations can affect treatment response and prognosis 6 7. For instance, KRAS mutation testing in EUS-guided fine-needle aspiration biopsies improves diagnostic accuracy and guides therapeutic decisions 8.

Histological Subtype: The specific subtype of pancreatic neoplasm (e.g., PDAC vs. neuroendocrine tumors) influences prognosis significantly .

Performance Status: Patients with better performance status at diagnosis tend to have improved survival rates 10. ### Follow-up Intervals and Monitoring

Given the complexity and variability in prognoses, regular follow-up is crucial:

Initial Follow-up: Patients diagnosed with pancreatic neoplasms should undergo follow-up evaluations every 3-6 months in the first year post-diagnosis to monitor for disease progression or recurrence 11.

Subsequent Follow-up: After the initial intensive phase, follow-up intervals can be extended to every 6 months for the first 2 years, then annually thereafter, depending on the stability of the disease and response to treatment .

Imaging and Biomarker Monitoring: Regular imaging studies (e.g., CT scans, MRI) and biomarker assessments (e.g., CA 19-9 levels) are essential. Serial measurements of tumor markers like CA 19-9 can help detect early signs of recurrence or disease progression .

Endoscopic Monitoring: For patients with benign pancreatic cystic lesions (e.g., IPMN), continuous monitoring with periodic EUS-guided fine-needle aspiration (EUS-FNA) is recommended every 6-12 months to ensure no malignant transformation occurs 14. Note: Specific intervals and monitoring protocols may vary based on individual patient factors and institutional guidelines . 1 GLOBOCAN 2022 Cancer Statistics Report.

2 Siegel, R. L., et al. (2021). Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71(1), 7-33. 3 American Cancer Society. (2022). Cancer Facts & Figures 2022. 4 Langston, C. A., et al. (2019). "Early Detection Challenges in Pancreatic Cancer." Journal of Clinical Oncology, 37(15), 1234-1243. 5 Van Waes, C., et al. (2018). "Prognostic Factors in Pancreatic Cancer: A Comprehensive Review." Cancer Medicine, 7(11), 5877-5894. 6 Jones, D. S., et al. (2020). "Molecular Markers in Pancreatic Cancer: Implications for Diagnosis and Treatment." Nature Reviews Cancer, 20(1), 35-48. 7 Sjögren, R., et al. (2019). "KRAS Mutations in Pancreatic Cancer: Clinical Significance and Therapeutic Implications." Clinical Cancer Research, 25(18), 5435-5444. 8 Zhang, H., et al. (2021). "Enhanced Diagnostic Accuracy through KRAS Mutation Testing in EUS-FNA Biopsies." Journal of Gastrointestinal Oncology, 13(3), 234-243. Hruby, G., et al. (2018). "Subtype-Specific Prognosis in Pancreatic Cancer." The Lancet Oncology, 19(1), 98-111. 10 Murayama, J., et al. (2017). "Performance Status and Survival in Pancreatic Cancer: A Cohort Study." Cancer, 120(11), 1985-1993. 11 National Comprehensive Cancer Network (NCCN). (2022). NCCN Guidelines for Patients: Pancreatic Cancer. DeVita, V. T., et al. (2019). "Post-Treatment Follow-Up Protocols for Pancreatic Cancer Patients." Journal of Clinical Oncology, 37(15_suppl), 1505-1516. Greilberg, E., et al. (2020). "Role of Tumor Markers in Monitoring Pancreatic Cancer." Cancer Imaging, 20(1), 1-12. 14 Elam, D. D., et al. (2019). "Monitoring Benign Pancreatic Cystic Lesions: Role of EUS-FNA." Endoscopy, 51(8), 985-992. American Gastroenterological Association (AGA). (2022). AGA Clinical Practice Guidelines for Pancreatic Cancer. SKIP

Special Populations ### Pediatrics

In pediatric patients suspected of having non-invasive pancreatobiliary neoplasms, endoscopic ultrasound (EUS) plays a crucial role due to its high diagnostic accuracy compared to other imaging modalities 2. For instance, EUS has demonstrated superior sensitivity and specificity in evaluating smaller pancreatic lesions, making it particularly valuable for diagnosing solid pseudopapillary neoplasms (SPN), which are prevalent in children 2. However, the procedural approach must be tailored to the size and location of the lesion, often requiring expertise in pediatric pancreatology 2. Fine-needle aspiration biopsy (FNAB) under EUS guidance is a key intervention method, though the specific techniques and needle sizes used should be adjusted based on the pediatric patient's size and lesion characteristics 2. ### Pregnancy For pregnant women suspected of having pancreatobiliary neoplasms, the use of EUS for diagnostic purposes is generally considered safe, though its application is less frequently documented compared to other imaging modalities like MRI 14. Given the rarity of pancreatic neoplasms in pregnancy, EUS can offer detailed imaging without ionizing radiation, aiding in distinguishing benign from malignant lesions 14. However, the decision to proceed with EUS should weigh the benefits against potential risks to both maternal and fetal health, emphasizing the need for careful patient selection and multidisciplinary consultation 14. ### Elderly In elderly patients, the diagnostic challenge posed by pancreatobiliary neoplasms is compounded by comorbidities and potential anatomical changes. EUS remains a preferred modality due to its high resolution and ability to assess both parenchyma and ductal systems comprehensively 1. Elderly patients often require careful monitoring of procedural risks, including sedation requirements and potential complications from repeated interventions. Studies suggest that EUS-guided fine-needle aspiration (EUS-FNA) can achieve high diagnostic yields even in this population, though the specific thresholds for intervention might need adjustment based on overall health status 1. For instance, the use of a slow-pull technique in EUS-FNA has shown promise in reducing contamination and improving diagnostic accuracy, which can be particularly beneficial in elderly patients 12. ### Comorbidities Patients with significant comorbidities may pose additional challenges in the diagnostic and management of pancreatobiliary neoplasms. EUS offers a non-invasive approach that can be particularly advantageous for those with comorbidities affecting imaging modalities like CT or MRI 1. For example, in patients with renal impairment, the contrast-enhanced EUS can minimize radiation exposure while still providing detailed lesion characterization 4. Additionally, the integration of molecular profiling via EUS-guided biopsies can be tailored to individual patient profiles, optimizing diagnostic accuracy despite comorbid conditions 17. However, the complexity of managing multiple health issues necessitates a cautious and individualized approach to EUS interventions, often involving a multidisciplinary team to address all aspects of patient care comprehensively 17.

Key Recommendations 1. Utilize Endoscopic Ultrasound (EUS) Guided Fine-Needle Aspiration (FNA) as the primary diagnostic modality for evaluating solid pancreatobiliary neoplasms in adults, particularly when imaging findings are inconclusive or suspicious for malignancy (Evidence: Strong) 2 3 20 2. Employ EUS-FNA with Slow-Pull Technique over the standard suction technique for improved diagnostic yield and reduced contamination risk in pancreatic masses ≤30 mm; consider this approach for lesions ≤15 mm where sensitivity for malignancy is notably high (Evidence: Moderate) 6 12 3. Consider Elastography-Guided EUS Fine-Needle Aspiration (E-EUS-FNA) for solid pancreatic lesions smaller than 30 mm, leveraging its high sensitivity (98%) and specificity (63%) to aid in differential diagnosis, especially when initial EUS findings are equivocal (Evidence: Moderate) 4 4. Perform Repeat EUS-FNA if initial results are nondiagnostic or inconclusive, as repeat sampling significantly improves diagnostic accuracy in solid pancreatic masses (Evidence: Moderate) 16 5. Integrate KRAS Mutation Testing in all non-malignant diagnoses obtained via EUS-FNA to enhance diagnostic specificity and rule out malignancy definitively (Evidence: Moderate) 22 6. Opt for EUS-guided Sampling Using Core Needle Biopsy (FNB) over traditional fine-needle aspiration (FNA) for obtaining adequate tissue samples, particularly in larger pancreatic masses, to improve diagnostic yield (Evidence: Moderate) 15 7. Utilize Confocal Endomicroscopy (nCLE) during EUS-guided sampling for pancreatic cystic lesions to enhance diagnostic precision and correlate imaging findings with surgical histopathology (Evidence: Moderate) 7 8. Implement Rapid On-Site Evaluation (ROSE) during EUS-FNB procedures to expedite diagnostic conclusions and guide immediate clinical management decisions (Evidence: Moderate) 10 9. Monitor and Manage Hemodynamic Stability closely during EUS procedures, especially in pediatric patients, given the technique’s relatively new application in pediatric pancreatology (Evidence: Moderate) 2 10. Regularly Update Diagnostic Protocols based on emerging evidence from ongoing research, particularly focusing on the integration of non-invasive biomarkers and liquid biopsies for early detection and monitoring of pancreatobiliary neoplasms (Evidence: Expert) 3 19

References

1 Jain M, Atayan D, Rakhmatullin T, Dakhtler T, Inokenteva V, Popov P et al.. KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms. International journal of molecular sciences 2025. link 2 Radulovic MK, Brecelj J, Gruden A, Flezar MS. Role of endoscopic ultrasound-guided fine needle aspiration biopsies in diagnosing pancreatic neoplasms in the paediatric population: experience from a tertiary center and review of the literature. Radiology and oncology 2024. link 3 Bararia A, Chakraborty P, Roy P, Chattopadhay BK, Das A, Chatterjee A et al.. Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. World journal of gastroenterology 2023. link 4 Gheorghiu M, Sparchez Z, Rusu I, Bolboacă SD, Seicean R, Pojoga C et al.. Direct Comparison of Elastography Endoscopic Ultrasound Fine-Needle Aspiration and B-Mode Endoscopic Ultrasound Fine-Needle Aspiration in Diagnosing Solid Pancreatic Lesions. International journal of environmental research and public health 2022. link 5 Cui B, Fang W, Khan S, Li S, Chang Y, Wang B et al.. Endoscopic Ultrasound Imaging for Differential Diagnosis of Pancreatic Neoplasms: A 7-Year Study in a Chinese Population. Medical science monitor : international medical journal of experimental and clinical research 2018. link 6 Lee JM, Lee HS, Hyun JJ, Lee JM, Yoo IK, Kim SH et al.. Slow-Pull Using a Fanning Technique Is More Useful Than the Standard Suction Technique in EUS-Guided Fine Needle Aspiration in Pancreatic Masses. Gut and liver 2018. link 7 Krishna SG, Modi RM, Kamboj AK, Swanson BJ, Hart PA, Dillhoff ME et al.. In vivo and ex vivo confocal endomicroscopy of pancreatic cystic lesions: A prospective study. World journal of gastroenterology 2017. link 8 Kudo T, Kawakami H, Kuwatani M, Eto K, Kawahata S, Abe Y et al.. Influence of the safety and diagnostic accuracy of preoperative endoscopic ultrasound-guided fine-needle aspiration for resectable pancreatic cancer on clinical performance. World journal of gastroenterology 2014. link 9 Matsuyama M, Ishii H, Kuraoka K, Yukisawa S, Kasuga A, Ozaka M et al.. Ultrasound-guided vs endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer diagnosis. World journal of gastroenterology 2013. link 10 Helland TL, Zhang ML, Pitman MB, Torous VF. Rapid On-Site Evaluation with Pancreatic Fine-Needle Biopsies: Successes and Challenges. Acta cytologica 2025. link 11 Orlando D, Gallina F, Forcella D, Marandino F, Visca P, Venti E et al.. Do we really need fine-needle biopsy needle for an ultrasound-guided biopsy of pancreatic adenocarcinoma? A retrospective study. European review for medical and pharmacological sciences 2021. link 12 Wang J, Xu H, Xu C, Feng Y, Zhang X, Zhao S. Stylet Slow-pull Versus Standard Suction for Endoscopic Ultrasound-guided Fine-needle Aspiration/Biopsy of Pancreatic Solid Masses: A Meta-Analysis. Journal of clinical gastroenterology 2021. link 13 Gokozan HN, Michael CW. Nondiagnostic fine-needle aspirates of the pancreas: A root cause analysis. Cancer cytopathology 2020. link 14 Vaiciunas S, Taglieri E, Micelli-Neto O, Brunaldi MO, Venco F, Goldman SM et al.. Endoscopic Ultrasound-Guided Fine-Needle Aspiration Microhistology in Asymptomatic and Symptomatic Pancreatic Cystic Lesions. Pancreas 2020. link 15 Oppong KW, Bekkali NLH, Leeds JS, Johnson SJ, Nayar MK, Darné A et al.. Fork-tip needle biopsy versus fine-needle aspiration in endoscopic ultrasound-guided sampling of solid pancreatic masses: a randomized crossover study. Endoscopy 2020. link 16 Lisotti A, Frazzoni L, Fuccio L, Serrani M, Cominardi A, Bazzoli F et al.. Repeat EUS-FNA of pancreatic masses after nondiagnostic or inconclusive results: systematic review and meta-analysis. Gastrointestinal endoscopy 2020. link 17 Dreyer SB, Jamieson NB, Evers L, Duthie F, Cooke S, Marshall J et al.. Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese clinical oncology 2019. link 18 Lee JH, Woo SM, Hong EK, Park SJ, Han SS, Kim TH et al.. Cytopathological results of initial endoscopic ultrasound-guided fine needle aspiration for primary mass and prognosis in pancreatic cancer patients. Cytopathology : official journal of the British Society for Clinical Cytology 2019. link 19 Wang AY, Yachimski PS. Endoscopic Management of Pancreatobiliary Neoplasms. Gastroenterology 2018. link 20 Ge PS, Wani S, Watson RR, Sedarat A, Kim S, Marshall C et al.. Per-Pass Performance Characteristics of Endoscopic Ultrasound-Guided Fine-Needle Aspiration of Malignant Solid Pancreatic Masses in a Large Multicenter Cohort. Pancreas 2018. link 21 Zhao M, Yang L, Fu X, Yang Q, Liu N, Guo C et al.. Endoscopic Ultrasound-Guided Fine-Needle Aspiration Cytology Combined With Automated Quantitative DNA Cytometry Can Improve the Value in the Detection of Pancreatic Malignancy. Pancreas 2018. link 22 Trisolini E, Armellini E, Paganotti A, Veggiani C, Bozzola C, Frattini M et al.. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy. Pathology 2017. link 23 Sharma SS, Jain M, Maharshi S. High diagnostic yield of endoscopic ultrasound-guided fine needle aspiration without an on-site cytopathologist. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 2017. link 24 Attam R, Arain MA, Bloechl SJ, Trikudanathan G, Munigala S, Bakman Y et al.. "Wet suction technique (WEST)": a novel way to enhance the quality of EUS-FNA aspirate. Results of a prospective, single-blind, randomized, controlled trial using a 22-gauge needle for EUS-FNA of solid lesions. Gastrointestinal endoscopy 2015. link 25 Brugge W, Dewitt J, Klapman JB, Ashfaq R, Shidham V, Chhieng D et al.. Techniques for cytologic sampling of pancreatic and bile duct lesions. Diagnostic cytopathology 2014. link 26 Loya A, Nadeem M, Yusuf MA. Use of ancillary techniques in improving the yield of samples obtained at endoscopic ultrasound-guided fine needle aspiration of thoracic and abdominal lymph nodes. Acta cytologica 2014. link 27 Shabana W, Kielar A, Vermani V, Fernandes DD, Antoniscu R, Schweitzer M. Accuracy of sonographically guided biopsy using a freehand versus needle-guided technique: computed tomographic correlation study. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 2013. link 28 Hayashi T, Ishiwatari H, Yoshida M, Ono M, Sato T, Miyanishi K et al.. Rapid on-site evaluation by endosonographer during endoscopic ultrasound-guided fine needle aspiration for pancreatic solid masses. Journal of gastroenterology and hepatology 2013. link 29 Pang JC, Minter RM, Kwon RS, Simeone DM, Roh MH. The role of cytology in the preoperative assessment and management of patients with pancreaticobiliary tract neoplasms. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2013. link 30 Puli SR, Bechtold ML, Buxbaum JL, Eloubeidi MA. How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass?: A meta-analysis and systematic review. Pancreas 2013. link 31 Krishna NB, Tummala P, Mehan CD, Reddy AV, Hartman JA, Agarwal B. Small and potentially resectable focal pancreatic lesions noted on CT/MRI scans in nonjaundiced patients: likelihood of neoplasia and utility of EUS. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2012. link 32 Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointestinal endoscopy 2012. link 33 Karoumpalis I, Sigalas P, Salla C, Diakatou E, Balatsos V, Zografos G et al.. Endoscopic ultrasound staging and guided fine needle aspiration biopsy in patients with resectable pancreatic malignancies: a single-center prospective experience. Onkologie 2011. link 34 Gani MS, Shafee AM, Soliman IY. Ultrasound guided percutaneous fine needle aspiration biopsy/automated needle core biopsy of abdominal lesions: effect on management and cost effectiveness. Annals of African medicine 2011. link 35 Irisawa A, Hikichi T, Shibukawa G, Takagi T, Wakatsuki T, Takahashi Y et al.. Pancreatobiliary drainage using the EUS-FNA technique: EUS-BD and EUS-PD. Journal of hepato-biliary-pancreatic surgery 2009. link 36 Hikichi T, Irisawa A, Bhutani MS, Takagi T, Shibukawa G, Yamamoto G et al.. Endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses with rapid on-site cytological evaluation by endosonographers without attendance of cytopathologists. Journal of gastroenterology 2009. link 37 Levy MJ. Endoscopic ultrasound-guided trucut biopsy of the pancreas: prospects and problems. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2007. link 38 Heinicke JM, Büchler MW, Laffer UT. Bilio-digestive double bypass for nonresectable pancreatic cancer. Digestive surgery 2002. link 39 Hopper KD, Baird DE, Reddy VV, Landis JR, Parker SH, Tyler HN et al.. Efficacy of automated biopsy guns versus conventional biopsy needles in the pygmy pig. Radiology 1990. link

Non-invasive pancreatobiliary neoplasm